We recognize that people living with complex conditions, such as rare diseases and cancer, need both practical and emotional support throughout their journey – yet many lack access to the help they need. We create clinically validated digital tools that address the unique challenges of disease and treatment-specific management, ensuring individuals have the support they need to live more confidently and thrive.

Founded in 2018 by John Drakenberg (Psychologist) and Oliver Fleetwood (Theoretical Computational Molecular Biophysicist), Alex Therapeutics believes that more can be done with psychology and technology to personalize healthcare and help people change their behavior to improve their quality of life. Early funding from King (makers of Candy Crush) set a foundation of user-engagement and gamification in their products, focusing on seamless digital experience combined with CBT-based interventions for meaningful health improvement.

The company partnered with Pfizer to develop a CBT-based digital smoking cessation program and has since expanded collaborations with other life sciences companies, establishing itself as a trusted partner for building digital therapeutics and therapy companions. Their modular technology platform supports new product development and regulated digital health products delivered globally. With a multidisciplinary team of over 20 experts across the EU and US, Alex Therapeutics integrates artificial intelligence and machine learning to enhance their products and user experience, aiming to provide high-quality, personalized care to millions worldwide.